ATE158818T1 - Auf proteinbasis beruhendes liefersystem - Google Patents
Auf proteinbasis beruhendes liefersystemInfo
- Publication number
- ATE158818T1 ATE158818T1 AT93913435T AT93913435T ATE158818T1 AT E158818 T1 ATE158818 T1 AT E158818T1 AT 93913435 T AT93913435 T AT 93913435T AT 93913435 T AT93913435 T AT 93913435T AT E158818 T1 ATE158818 T1 AT E158818T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- delivery system
- date jan
- phage
- capsids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/18011—Details ssRNA Bacteriophages positive-sense
- C12N2795/18111—Leviviridae
- C12N2795/18141—Use of virus, viral particle or viral elements as a vector
- C12N2795/18142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/803—Containing biological material in its interior
- Y10S977/804—Containing nucleic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/806—Virus-based particle with exterior chemical attachment
- Y10S977/808—Exterior attachment for targeting, e.g. drug targeting
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/916—Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/92—Detection of biochemical
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Optics & Photonics (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- AIDS & HIV (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Screw Conveyors (AREA)
- Warehouses Or Storage Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929213601A GB9213601D0 (en) | 1992-06-26 | 1992-06-26 | Protein based delivery system |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE158818T1 true ATE158818T1 (de) | 1997-10-15 |
Family
ID=10717784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT93913435T ATE158818T1 (de) | 1992-06-26 | 1993-06-25 | Auf proteinbasis beruhendes liefersystem |
Country Status (12)
Country | Link |
---|---|
US (1) | US6159728A (de) |
EP (1) | EP0648272B1 (de) |
JP (1) | JP3634358B2 (de) |
KR (1) | KR100240515B1 (de) |
AT (1) | ATE158818T1 (de) |
AU (1) | AU679919B2 (de) |
CA (1) | CA2138414A1 (de) |
DE (1) | DE69314339T2 (de) |
ES (1) | ES2110097T3 (de) |
GB (2) | GB9213601D0 (de) |
NZ (1) | NZ253298A (de) |
WO (1) | WO1994000588A1 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4335025A1 (de) * | 1993-10-14 | 1995-04-20 | Boehringer Ingelheim Int | Endosomolytisch wirksame Partikel |
DE19618797C2 (de) * | 1996-05-10 | 2000-03-23 | Bertling Wolf | Vehikel zum Transport molekularer Substanz |
US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
WO1998006828A1 (fr) * | 1996-08-09 | 1998-02-19 | Dnavec Research Inc. | Phage lie au signal de localisation nucleaire |
WO1999066061A1 (fr) * | 1998-06-18 | 1999-12-23 | Dnavec Research, Inc. | Phage de transfert d'acide nucleique |
IL142025A0 (en) * | 1999-07-20 | 2002-03-10 | Morphosys Ag | Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds |
US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
US7128911B2 (en) * | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
JP4516748B2 (ja) | 2001-09-14 | 2010-08-04 | サイトス バイオテクノロジー アーゲー | ウィルス様粒子中への免疫賦活物質のパッケージ化:調製法および使用法 |
JP4360906B2 (ja) * | 2001-09-14 | 2009-11-11 | サイトス バイオテクノロジー アーゲー | ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化 |
RU2322258C2 (ru) * | 2001-11-07 | 2008-04-20 | Цитос Байотекнолоджи Аг | Антигенные матрицы для лечения заболевания костей |
BR0311800A (pt) * | 2002-07-19 | 2005-03-22 | Cytos Biotechnology Ag | Conjugados ghrelina-veìculo |
US20060210588A1 (en) * | 2003-03-26 | 2006-09-21 | Cytos Biotechnology Ag | Hiv-peptide-carrier-conjugates |
CA2517675A1 (en) * | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
US7537767B2 (en) * | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
AU2005291231B2 (en) * | 2004-10-05 | 2010-12-23 | Cytos Biotechnology Ag | VLP-antigen conjugates and their uses as vaccines |
CN101119749A (zh) * | 2004-10-25 | 2008-02-06 | 赛托斯生物技术公司 | 肠抑胃肽(gip)抗原阵列及其用途 |
WO2006095345A2 (en) * | 2005-03-08 | 2006-09-14 | Ramot At Tel-Aviv University Ltd. | Targeted drug-carrying bacteriophages |
US7767212B2 (en) * | 2005-03-18 | 2010-08-03 | Cytos Biotechnology Ag | CAT allergen conjugates and uses thereof |
WO2006125821A2 (en) * | 2005-05-26 | 2006-11-30 | Cytos Biotechnology Ag | Scalable fermentation process |
US20070184068A1 (en) | 2005-12-14 | 2007-08-09 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
NZ573622A (en) | 2006-06-12 | 2011-12-22 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
DK2190987T3 (da) | 2007-08-21 | 2013-02-18 | Morphosys Ag | Fremgangsmåder til dannelse af disulfidbindinger |
JP5645840B2 (ja) | 2008-12-02 | 2014-12-24 | 株式会社Wave Life Sciences Japan | リン原子修飾核酸の合成方法 |
CN102596204B (zh) | 2009-07-06 | 2016-11-23 | 波涛生命科学有限公司 | 新的核酸前药及其使用方法 |
EP2620428B1 (de) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetrische hilfsgruppe |
JP6128529B2 (ja) | 2011-07-19 | 2017-05-17 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | 官能化核酸の合成のための方法 |
PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
WO2014012081A2 (en) | 2012-07-13 | 2014-01-16 | Ontorii, Inc. | Chiral control |
AU2013287630B2 (en) | 2012-07-13 | 2017-05-25 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
EP3095460A4 (de) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum |
JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
US10160969B2 (en) | 2014-01-16 | 2018-12-25 | Wave Life Sciences Ltd. | Chiral design |
RU2695136C1 (ru) * | 2018-06-19 | 2019-07-22 | Общество с ограниченной ответственностью Биотехнология (ООО Биотехнология) | Онколитический способ терапии рака молочной железы. |
EP4141110A1 (de) | 2020-04-24 | 2023-03-01 | Obshchestvo S Ogranichennoy Otvetstvennost'yu "Ingenik" | Verfahren zur herstellung von bakteriophagenteilchen der gattung levivirus |
JP2024505060A (ja) * | 2021-01-27 | 2024-02-02 | エイラ・セラピューティクス・インコーポレイテッド | Pnma2ベースのキャプシド及びその使用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8608850D0 (en) * | 1986-04-11 | 1986-05-14 | Diatech Ltd | Packaging system |
EP0652967B1 (de) * | 1990-08-15 | 1998-02-04 | Therion Biologics Corporation | Selbstständig zusammenfügende replikationsdefekte hybride viruspartikel |
AU660629B2 (en) * | 1990-10-01 | 1995-07-06 | University Of Connecticut, The | Targeting viruses and cells for selective internalization by cells |
US5298244A (en) * | 1990-10-25 | 1994-03-29 | University Of Saskatchewan | Assembled viral particles and their use in a vaccine to rotaviral disease |
GB9101550D0 (en) * | 1991-01-24 | 1991-03-06 | Mastico Robert A | Antigen-presenting chimaeric protein |
GB9114003D0 (en) * | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
-
1992
- 1992-06-26 GB GB929213601A patent/GB9213601D0/en active Pending
-
1993
- 1993-06-25 AT AT93913435T patent/ATE158818T1/de not_active IP Right Cessation
- 1993-06-25 KR KR1019940704768A patent/KR100240515B1/ko not_active IP Right Cessation
- 1993-06-25 WO PCT/GB1993/001338 patent/WO1994000588A1/en active IP Right Grant
- 1993-06-25 CA CA002138414A patent/CA2138414A1/en not_active Abandoned
- 1993-06-25 ES ES93913435T patent/ES2110097T3/es not_active Expired - Lifetime
- 1993-06-25 JP JP50216894A patent/JP3634358B2/ja not_active Expired - Fee Related
- 1993-06-25 GB GB9313186A patent/GB2268492B/en not_active Revoked
- 1993-06-25 US US08/360,694 patent/US6159728A/en not_active Expired - Fee Related
- 1993-06-25 DE DE69314339T patent/DE69314339T2/de not_active Expired - Fee Related
- 1993-06-25 EP EP93913435A patent/EP0648272B1/de not_active Expired - Lifetime
- 1993-06-25 NZ NZ253298A patent/NZ253298A/en unknown
- 1993-06-25 AU AU43507/93A patent/AU679919B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
KR950702248A (ko) | 1995-06-19 |
JPH07508168A (ja) | 1995-09-14 |
GB2268492A (en) | 1994-01-12 |
EP0648272A1 (de) | 1995-04-19 |
ES2110097T3 (es) | 1998-02-01 |
AU679919B2 (en) | 1997-07-17 |
KR100240515B1 (ko) | 2000-01-15 |
CA2138414A1 (en) | 1994-01-06 |
GB9213601D0 (en) | 1992-08-12 |
DE69314339T2 (de) | 1998-02-26 |
NZ253298A (en) | 1996-03-26 |
GB9313186D0 (en) | 1993-08-11 |
JP3634358B2 (ja) | 2005-03-30 |
WO1994000588A1 (en) | 1994-01-06 |
AU4350793A (en) | 1994-01-24 |
DE69314339D1 (de) | 1997-11-06 |
EP0648272B1 (de) | 1997-10-01 |
US6159728A (en) | 2000-12-12 |
GB2268492B (en) | 1996-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE158818T1 (de) | Auf proteinbasis beruhendes liefersystem | |
DE69427650D1 (de) | Verbindungen mit wachstumshormon-freisetzenden eigenschaften | |
DE69428040T2 (de) | Orale darreichungsform | |
FI95768C (fi) | Emättimensisäinen antosysteemi | |
HRP20010877B1 (en) | Composition for prevention and treatment of amyloidogenic disease | |
MY132189A (en) | Recombinant obese (ob) proteins | |
DE69530844D1 (de) | Verfahren und substanzen gegen protozoen | |
ATE258057T1 (de) | Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen | |
DE69840024D1 (de) | Antimikrobielle Peptide, abstammend von Ubiquicidin | |
PT983300E (pt) | Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia | |
DE69102069T2 (de) | 5-aminosalicylsäurederivate zur therapie chronisch entzündlicher baucherkrankungen. | |
MX9206339A (es) | Nueva proteina inhibidora de trombina a partir de chinches de monte | |
NO962927D0 (no) | Hestearteritt-virus peptider, antistoffer og deres anvendelse i en diagnostisk test | |
DE69325512D1 (de) | Verwendung von remacemid zur behandlung des morbus parkinson | |
ATE282704T1 (de) | Isolierte und gereinigte humane lösliche guanylylcyclase alpha1/beta1 (hsgc alpha1/beta1) | |
MX9604539A (es) | Aminoacidos modificados para la distribucion de farmaco. | |
NZ336371A (en) | Human gene therapy using DNA/RNA cassette expression systems | |
TH31634A (th) | เพพไทด์ชนิดใหม่ที่เหมาะสมสำหรับใช้ในการบำบัดรักษาที่กดภูมิคุ้มกันที่มีความจำเพาะต่อแอนติเจน | |
AR004338A1 (es) | Uso de una proteina derivada de una quimioquina para preparar un medicamento para tratar y prevenir la sepsis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |